<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<REGINFO_RIN_DATA xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" RUN_DATE="2026-04-04-04:00" xsi:noNamespaceSchemaLocation="https://www.reginfo.gov/public/xml/REGINFO_XML_Ver10262011.xsd">
    <RIN_INFO>
        <RIN>0910-AH48</RIN>
        <PUBLICATION>
            <PUBLICATION_ID>201804</PUBLICATION_ID>
            <PUBLICATION_TITLE>Unified Agenda of Federal Regulatory and Deregulatory Actions</PUBLICATION_TITLE>
        </PUBLICATION>
        <AGENCY>
            <CODE>0910</CODE>
            <NAME>Food and Drug Administration</NAME>
            <ACRONYM>FDA</ACRONYM>
        </AGENCY>
        <PARENT_AGENCY>
            <CODE>0900</CODE>
            <NAME>Department of Health and Human Services</NAME>
            <ACRONYM>HHS</ACRONYM>
        </PARENT_AGENCY>
        <RULE_TITLE>Amending Premarket Regulations That Require Multiple Copies and Specify Paper Copies to be Allowed in Electronic Format </RULE_TITLE>
        <ABSTRACT><![CDATA[<!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>The Food and Drug Administration (FDA or Agency) is amending its regulations to remove requirements to submit multiple paper copies of medical device regulatory pre-submissions and submissions and replace them with one copy in an electronic format. We are revising premarket submissions and registration and listing regulations to make an efficient and effective electronic submission program.</p>
</body>
</html>]]></ABSTRACT>
        <PRIORITY_CATEGORY>Substantive, Nonsignificant</PRIORITY_CATEGORY>
        <RIN_STATUS>Previously Published in The Unified Agenda</RIN_STATUS>
        <RULE_STAGE>Final Rule Stage</RULE_STAGE>
        <MAJOR>Undetermined</MAJOR>
        <UNFUNDED_MANDATE_LIST>
            <UNFUNDED_MANDATE>No</UNFUNDED_MANDATE>
        </UNFUNDED_MANDATE_LIST>
        <EO_13771_DESIGNATION>Deregulatory</EO_13771_DESIGNATION>
        <CFR_LIST>
            <CFR>21 CFR 807</CFR>
            <CFR>21 CFR 812</CFR>
            <CFR>21 CFR 814</CFR>
        </CFR_LIST>
        <LEGAL_AUTHORITY_LIST>
            <LEGAL_AUTHORITY>21 U.S.C. 321</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 331</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 351 to 353</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 355</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 360</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 360h to 360j</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 371 and 372</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 374 and 375</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 379</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 379e</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 381</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 382</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 393</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 745A</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>42 U.S.C. 216</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>42 U.S.C. 241</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>42 U.S.C. 262</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>42 U.S.C. 263b to 26n</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>42 U.S.C. 264</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>42 U.S.C. 271</LEGAL_AUTHORITY>
        </LEGAL_AUTHORITY_LIST>
        <LEGAL_DLINE_LIST/>
        <RPLAN_ENTRY>No</RPLAN_ENTRY>
        <TIMETABLE_LIST>
            <TIMETABLE>
                <TTBL_ACTION>Direct Final Rule</TTBL_ACTION>
                <TTBL_DATE>05/00/2018</TTBL_DATE>
            </TIMETABLE>
        </TIMETABLE_LIST>
        <RFA_REQUIRED>No</RFA_REQUIRED>
        <SMALL_ENTITY_LIST>
            <SMALL_ENTITY>No</SMALL_ENTITY>
        </SMALL_ENTITY_LIST>
        <GOVT_LEVEL_LIST>
            <GOVT_LEVEL>None</GOVT_LEVEL>
        </GOVT_LEVEL_LIST>
        <FEDERALISM>No</FEDERALISM>
        <ENERGY_AFFECTED>No</ENERGY_AFFECTED>
        <PRINT_PAPER>No</PRINT_PAPER>
        <INTERNATIONAL_INTEREST>No</INTERNATIONAL_INTEREST>
        <AGENCY_CONTACT_LIST>
            <CONTACT>
                <FIRST_NAME>Madhusoodana</FIRST_NAME>
                <LAST_NAME>Nambiar</LAST_NAME>
                <TITLE>Policy Advisor</TITLE>
                <AGENCY>
                    <CODE>0910</CODE>
                    <NAME>Food and Drug Administration</NAME>
                    <ACRONYM>FDA</ACRONYM>
                </AGENCY>
                <PHONE>301 796-5837</PHONE>
                <EMAIL>madhusoodana.nambiar@fda.hhs.gov</EMAIL>
                <MAILING_ADDRESS>
                    <STREET_ADDRESS>10903 New Hampshire Avenue, Building 66, Room 5519,</STREET_ADDRESS>
                    <CITY>Silver Spring</CITY>
                    <STATE>MD</STATE>
                    <ZIP>20993</ZIP>
                </MAILING_ADDRESS>
            </CONTACT>
        </AGENCY_CONTACT_LIST>
    </RIN_INFO>
</REGINFO_RIN_DATA>
